PUBLICATIONS

(Selected publications in chronological order)

Marion RW, Wiznia AA, Hutcheon RG, Rubinstein: Fetal AIDS Syndrome Score: Correlation between severity of dysmorphism and age at diagnosis of immune deficiency. Am. J. Dis. Child, 141(7):429-431, 1987.

Marion RW, Wiznia AA, Quazi QH, Shepard: Fetal AIDS Syndrome. Birth Defects Encyclopedia, 1988.

Diamond GW, Gurdin PG, Wiznia AA, Belman AL, Rubinstein A, Cohen HJ: The effect of congenital HIV infection on the neurodevelopmental status of boarder babies in foster care. Developmental Medicine & Child Neurology, 32(11):999-1005, 1990.

Schwartz LJ, St. Louis Y, Wu R, Wiznia AA, Rubinstein A, Saenger P: Endocrine function in children with Human Immunodeficiency Virus. Am J Dis Child, 145(3):330-333, 1991.

Hand IL, Wiznia AA, Checola RT, Kim MH, Noble LM, Daley TJ, Yoon JJ: Human Immunodeficiency Virus seropositivity in critically ill neonates in the South Bronx. Pediatr Infect Dis J, 11(1):39-42, 1992.

Hand IL, Wiznia AA, Porricolo M, Lambert G, Caspe WB: Aerosolized pentamidine for prophylaxis for pneumocystis carinii pneumonia in HIV-Infected infants. Pediatr Infect Dis J, 13:100-104, 1994.

Nozyce M, Hoberman M, Arpadi S, Wiznia AA, Lambert G, Dobroszycki J, Chang CJ, St. Louis Y: A 12 month study of the effects of oral ZDV on neurodevelopmental functioning in a cohort of vertically infected inner city children. AIDS, 8(5):635-639, 1994.

Wiznia AA, Lambert G, Dobrosyzcki J, Porricolo M, Chelyapov N, Israeli V, Brunnell P, Conroy J, Liu H.K, Baron M, Gold J: Virologic, immunologic and clinical evaluation of HIV seroreverting children. Journal of Pediatrics, 125(3):352-355, 1994.

Wiznia AA, Crane M, Lambert G, Sansary J, Harris A, Solomon L: Zidovudine use to reduce perinatal HIV-1 transmission in an urban medical center. Journal of American Medical Association, 275(19):1504-06, 1996.

Dobroszycki J, Abadi J, Lambert G, Beenhouwer DO, Truong TH, Wiznia AA: Testicular abscess due to streptococcus pneumoniae in an infant with Human Immunodeficiency Virus Infection. Clin Infect Dis, 24:84-5, 1997.

McKinney R, Johnson G, Stanley K, Yong F, Keller A, O'Donnell K, Brouwers P, Wiznia AA, Mitchell C, McNamara J, Mofenson L,Wells B, Hodge J: A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in symptomatic, therapy-naive, HIV-1 infected children ACTG 300. Journal of Pediatrics, 133(4):500-8, 1998.

Pavlakis S, Lu D, Frank Y, Wiznia AA, Elderberg D, Barnett T, Hyman R: Brain lactate and N-acetylaspartate in pediatric AIDS encephalopathy. Annals Neurology, 19:383-385, 1998.

Krogstad P, Wiznia AA, Luzuriaga K, Danker W, Nielsen K, Kerr B, Hendricks A, Gersten M, Boczany B, Spector S, Bryson Y: Treatment of Human Immunodeficiency Virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis, 28(5):1109-18, 1999.

McGowan JP, Crain M, Wiznia AA, Blum S: Combination antiretroviral therapy in Human Immunodeficiency Virus-Infected pregnant women. American Journal of Obstetrics and Gynecology, 94(5 pt 1):641-6, 1999.

VanDyke R, Korber B, Popek E, Macken C, Widmayer S, Bardeguez A, Hanson C, Wiznia AA, Luzuriaga K, Viscarello R, Wolinsky S: The Ariel Project: A prospective cohort study of Maternal-Child Transmission of Human Immunodeficiency Virus Type 1 in the era of maternal antiretroviral therapy. Journal of Infectious Diseases, 179(2):319-28, 1999.

Wilson CC, Brown RC, Korber BT, Wilkes BM, Ruhl DJ, Sakamoto D, Kunstman K, Luzuriaga K, Hanson IC, Widmayer SM, Wiznia AA, Clapp S, Ammann AJ, Koup RA, Wolinsky SM, Walker BD: Frequent detection of escape from cytotoxic T-Lymphocyte recognition in Perinatal Human Immunodeficiency Virus (HIV) type 1 transmission: The Ariel Project for the Prevention of Transmission of HIV from Mother to Infant. Journal of Virology, 73(5):3975-85, 1999.

Borkowsky W, Stanley K, Douglas SD, Lee S, Wiznia AA, Pelton S, Yogev R, McIntosh K, Nachman and the Pediatric AIDS Clinical Trials Group 338 Study Team. Immunologic response to combination nucleoside plus protease inhibitor therapy in stable antiretroviral-experienced HIV-infected children. Journal of Infectious Diseases, 182:96-103, 2000.

Nachman S, Stanley K, Yogev R, Pelton S, Wiznia AA, et al.: A Randomized Trial of One or Two Nucleoside Analog Therapy in Stable Antiretroviral Experienced HIV-Infected Children (PACTG 338). Journal of American Medical Association, 283(4):492-8, 2000.

Spiegel HML, Chandwani R, Sheehy ME, Dobroszycki J, Fennelly G, Wiznia AA, Radding J, Rigaud M, Pollack H, Borkowsky W, Rosenberg M, Nixon DF.: The impact of early initiation of antiretroviral drug treatment on the HIV-1 specific cytotoxic T cell responses in HIV-1 infected children. J Infect Dis, 182:88-95, 2000.

Wiznia AA, Stanley K, Krogstad P, et al.: Combination nucleoside analogue(s) reverse transcriptase inhibitors plus nevirapine, nelfinavir or ritonavir in stable antiretroviral therapy-experienced HIV-infected children. Results of randomized controlled trial-Pediatric AIDS Clinical Trials Group 377. AIDS Research and Human Retroviruses 16(12):1113-1121, 2000.

Eshelmann SH, Krogstad P, Jackson JB, Wang YG, Lee S, Wei LJ, Cunningham S, Wantman M, Wiznia A, Johnson G, Nachman S, Palumbo P. Analysis of HIV-1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377). J Infect Dis, 183:1732-38, 2001.

Llonrens XS, Nelson RP, Emmanuel P, Wiznia AA, Mitchell C, Church J, Sleasman J, Van Dyke R, Richardson CG, Cutrell A, Spreen W, Hetherington S, and the CNAA3006 Study Team: A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine and zidovudine versus lamivudine and zidovudine in previously treated HIV-1 infected Children. Pediatrics, 107(1):e4, 2001.

Krogstad P, Eshleman SH, Geng Y, Jackson J B, Wantman M, Korber B, Lang D, Wiznia A, Johnson G, Nachman S, Palumbo P. Vertical transmission of Subtypes D and A/G Human immunodeficiency virus Type 1 in the United States. AIDS Res Hum Retroviruses (United States), 18(6) p413-7, Apr 2002.

Krogstad P, Lee S, Johnson G, Nachman S, et al and Wiznia AA for the Pediatric AIDS Clinical Trials Group Study Team. Combination nucleoside analogue(s) reverse transcriptase inhibitors plus nevirapine, nelfinavir or ritonavir in stable antiretroviral therapy-experienced HIV-infected children. Week 48 analysis of Pediatric AIDS Clinical Trials Group 377. Clinical Infectious Diseases, 34:991-1001, 2002.

Nachman S, Lindsey JC, Pelton SI, Mofenson L, McIntosh K, Wiznia A, Stanley K, Yogev R. Growth in HIV-Infected Children Receiving Ritonavir-Containing Antiretroviral Therapy. Arch Pediatr Adolesc Med (United States), 156(5) p497-503, May 2002.

Van Dyke RB, Lee S, Johnson GM, Wiznia A, Mohan K, Stanley K, Morse EF, Krogstad PA, Nachman S. Reported Adherence as a Determinant of Response to Highly Active Antiretroviral Therapy in HIV-Infected Children. Pediatrics (United States), 109(4) pe61, Apr 2002.

Yogev R, Lee S, Wiznia AA, et al. for the Pediatric AIDS Clinical Trials Group 338 Study Team. Stavudine, nevirapine and ritonavir in stable, antiretroviral therapy experienced HIV-infected children (Pediatric AIDS Treatment Group Protocol 338, Step 2). Pediatr Infect Dis J (United States), 21(2) p119-25, Feb 2002.

Wiznia AA, Cunningham C. Pediatric Antiretroviral Therapy. Office of the Medical Director, AIDS Institute, New York State Department of Health. Guidelines_Update@hivguidelines.org 4/2002.

Okunseri, C., Badner, V., Wiznia, A., Rosenberg, M.: Dental visits by pediatric HIV-infected medical patients. NY State Dental Journal, in press.

Okunseri, C., Badner, V., Wiznia, A.A., Rosenberg, M.: Prevalence of oral lesions and CD4+ percent in HIV-infected children on antiretroviral therapy. AIDS Patient Care and STDs, in press.

<back to top>